Shuimu BioSciences, a biotech start-up working towards the implementation of cryo-EM into drug discovery, got an investment from the internet tech giant ByteDance last October. Shuimu uses not only cutting-edge cryo-EM technology, but also combines it with machine learning for the optimized 3D atomic modeling and more. Shuimu claims to rationalize the drug discovery applying their cryo-EM technology, getting the resolution of 1.8 Å for some protein targets.
This content available exclusively for BPT Mebmers
Topics: Industry Trends